Q4
4.6.2024 14:01:34 CEST | Business Wire | Press release
Q4 Inc. (“Q4” or “the company”), the IR Ops platform, unveils survey results focused on a variety of topics to better understand Investor Relations Officers (“IROs”) goals, challenges and use cases within AI. Over 200 IROs engaged with the survey, providing in depth insight for what the future of IR may hold and a clear roadmap on how IR technology partners can help.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604548445/en/
The Evolving Role of the IRO (Graphic: Business Wire)
With small teams and tight budgets, IR programs are laser focused on driving greater efficiency and effectiveness in their IR strategies. The top expectations from IR management to IROs are clear; shareholder retention, improving analyst ratings and coverage, and enhancing the quality of investor meetings. With the majority of IR teams composed of just a few members, these mandates are challenging to achieve. Therefore, this data solidifies the necessary need to deliver on these expectations in a timely, efficient, and effective way.
IROs were asked what tools they would use if they had unlimited resources to enhance their success. Over 50% of those surveyed expressed a desire for additional tools that provide impact reporting and progress tracking. This data corresponds with the top goals and challenges uncovered in the survey, with respondents identifying investor and analyst targeting/engagement as their primary goal and 40% of them reporting it as their biggest challenge. Furthermore, 43% of IROs stated that identifying the right individuals for outreach is their top challenge when trying to attract new investors.
Advancements in technology, particularly the use of AI, offer effective solutions for IROs to address these challenges. A significant majority (73%) of IROs believe in the potential of AI to make teams more effective and save time on administrative tasks, while 60% think AI will allow more time for strategic initiatives. However, there is still a gap in understanding and integrating technology effectively, as over 50% of respondents are unsure where AI would be most useful and how to best utilize it for success.
Darrell Heaps, Founder and CEO of Q4, stated, “Through our recent survey and in discussions with our existing clients, including members of our client advisory board, we understand the challenges that IROs face and are committed to providing them with the tools they need to succeed. In order to mitigate some of the issues IROs are facing, our research found that there is a need for education around how technology, including AI, can help to increase efficiency.”
Q4’s research substantiates the importance of the types of tools being used by IROs, how they access the knowledge to use them effectively, and how to measure and report outcomes when using AI. By automating routine IR tasks, IROs can devote more time and resources to strategic planning, fostering meaningful relationships and driving premium valuations, which are crucial for long-term success.
For additional information on the research conducted by Q4, please contact media@q4inc.com.
About Q4 Inc.
Q4 Inc. is the first IR Ops Platform with the world’s largest set of proprietary investor data, purpose-built to remove obstacles between public companies and their investors. Q4 gives investor relations leaders and their teams the tools to attract, manage, and understand investors — all in one place. The AI-enabled Q4 IR Ops Platform boasts a simple yet powerful IR website management system, frictionless events software, a robust analytics engine, a streamlined investor CRM, and shareholder intelligence with enhanced metrics to elevate investor targeting strategies. Q4 delivers the data, insights, and workflows that give IR teams the power to focus on what really matters: strategy, relationships, and driving premium valuations for their companies.
The company is a trusted partner to more than 2,600 public companies globally, including many of the most respected brands in the world, and maintains an award winning culture where team members grow and thrive.
Q4 is headquartered in Toronto, with offices in New York and London. Learn more at www.q4inc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604548445/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hologic Signs Definitive Agreement to Acquire Reveal Genomics19.10.2026 21:30:00 CEST | Press release
Acquisition would expand Hologic’s oncology diagnostics portfolio to help inform treatment decisions for more women with breast cancer Hologic, a global leader in women’s health, today announced that it has signed a definitive agreement to acquire Reveal Genomics, a precision oncology company based in Barcelona, Spain, that develops advanced genomic diagnostic tests to help personalized cancer treatment, including its HER2DX test to help optimize therapy for patients with HER2-positive breast cancer. Breast cancer remains one of the most significant health challenges women face today. Reveal Genomics’ tests are highly complementary to Hologic’s existing oncology diagnostics, including the Breast Cancer Index® (BCI) test, the guideline-recognized genomic assay to help inform decisions regarding extended endocrine therapy in women with HR+ early-stage breast cancer. The combination of Hologic’s existing testing with Reveal Genomics’ portfolio represents a significant expansion of Hologic
An Active Role in Freshness: ProAmpac Introduces ProActive Intelligence Shelf Protect19.10.2026 21:27:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, introduces ProActive Intelligence™ Shelf Protect (SP) Series, giving food producers a new way to help preserve product quality and reduce costly spoilage. Designed for select meat, seafood, and dairy applications, the technology is FDA- and USDA-compliant for intended uses in fresh beef, fresh pork, cooked sausage, deli meat, fresh salmon, and fresh cheese. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019305953/en/ Clearshield®-SP Shrink Bag This direct food-contact biotechnology packaging helps reduce microbial growth associated with food spoilage in intended applications, supporting longer shelf life throughout storage and distribution. Shelf Protect’s patented biotechnology is built directly into food-contact packaging film. “For meat processors, every product lost represents an investment in production, packaging, and distribution that goes unreal
Vedanta Ltd Doubles Zinc Capacity in South Africa with US$ 600 Mn investment19.10.2026 19:19:00 CEST | Press release
Vedanta Limited doubled its annual zinc production capacity to 500,000 tonnes1in South Africa through an investment of nearly US$ 600 Mn at Gamsberg (Phase II) at Vedanta Zinc International (VZI). Gamsberg has one of the world’s most significant zinc deposits and is VZI’s flagship zinc mine. Inaugurated by South African President Cyril Ramaphosa and Vedanta Limited Director Priya Agarwal-Hebbar, this expansion marks one of the decade’s largest mining investments in South Africa. It advances Vedanta Limited’s position as the world’s largest2 zinc producer, with a vision of achieving 3 million tonnes of annual production across India and South Africa. Of this, 2 million tonnes are targeted from its subsidiary, Hindustan Zinc Limited the world’s largest integrated zinc producer, while Vedanta Zinc International business aims to contribute 1 million tonnes annually. This expansion strengthens the ZAR 21 Bn (nearly US$ 1.5 Bn) investment commitment Vedanta made at the 2018 South Africa Inve
Unlocking Digital Gold’s US$700bn Opportunity19.10.2026 18:00:00 CEST | Press release
The digital gold market, worth US$45–55bn today, could unlock up to US$700bn in latent demand, according to new research from World Gold Council and Boston Consulting Group. The report points to substantial untapped appetite among retail investors, with nearly nine in ten surveyed saying they would consider digital gold under the right conditions. The US$700bn opportunity represents the report’s estimate of total latent demand that could be released if today’s barriers to adoption were removed, rather than a near-term forecast. The report’s five-year base case sees digital gold growing by around 27% a year to US$160–170bn by 2031. That could rise to US$270–280bn over the same time if more barriers fall faster. Momentum is already building as financial markets undergo a broader digital transformation, bringing tokenised investment products increasingly into the mainstream. Tokenised gold, one segment of the digital gold market alongside vaulted digital gold, has grown fivefold in value
Roquette Brings Broad Portfolio of Excipient Solutions and Technical Expertise to AAPS PharmSci 360 202619.10.2026 16:00:00 CEST | Press release
Roquette, a global leader in plant-based ingredients, excipients and pharmaceutical solutions, will showcase its expansive portfolio of excipients, capsules, coatings, and biopharma solutions at AAPS PharmSci 360 2026. The conference and trade show will take place October 26-28 in New Orleans, Louisiana, USA. At Booth 1100 in the exhibit hall, Roquette’s Health & Pharma Solutions team will share their expertise across controlled-release technologies, hydroxypropyl beta-cyclodextrins, and sustainable formulation approaches, alongside a comprehensive portfolio of innovative solutions designed to address the evolving needs of pharmaceutical developers. “AAPS PharmSci 360 is a key opportunity to share our latest innovations, as well as highlight the breadth and depth of our scientific know-how that helps our customers solve complex formulation challenges,” said Peter Freed, Head of Technical Service & Development North America for Roquette’s Health & Pharma Solutions Business Unit. “From a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
